The Royal Wolverhampton NHS Trust Logo
Homepage Research

Research

The Royal Wolverhampton NHS Trust (RWT) facilitates research of the highest quality to improve the care provided to patients and achieve the best clinical outcomes.

Research is a core component of our activity and is key to advancements in patient care.

Clinical research is an essential requirement to improve understanding of which treatments work best.

At RWT we continually strive to ensure our patients are offered early participation in suitable research as part of their treatment and care choice.

Contact the Research and Development (R&D) Directorate


  • Call us: 01902 695065
  • Email us: rwh-tr.RDadminteam@nhs.net
  • Write to us: R&D Directorate, The Royal Wolverhampton NHS Trust, Building 9 (The Chestnuts), New Cross Hospital, Wolverhampton Road, Wolverhampton, West Midlands, WV10 0QP.

Or a member of the team:

Find out what’s been happening


There’s always so much going on with research and we like to share our good news. Click this link to visit our news pages and see all the latest stories about research.

Information for patients


During your care with us, your doctor or a member of the team looking after you may talk to you about research and ask if you would like to join a study.

You will be given written information about the study and you will be encouraged to ask questions and be given time to think about what is involved. You will then be contacted again to confirm if you would like to take part.

You don’t have to wait to be asked to take part in research; we would encourage you to ask your doctor or member of their team, if there is any research you can take part in.

You can also visit the National Institute For Health And Social Care Research (NIHR) website to find out more information about trials.

Our R&D Directorate is responsible for supporting and facilitating research and innovation throughout the organisation. This includes ensuring:

  • all research run at the Trust is ethically sound and in line with all legal requirements
  • it is delivered appropriately and safely
  • it supports the development of clinical services provided here at the Trust, supports our staff, and enhances the care and treatment of our patients

The Trust is involved in many kinds of research, across a variety of clinical specialities, including pharmaceutical drug trials, genetic research, medical device trials and questionnaire studies, to name just a few.

Research studies are run across services provided at New Cross and West Park Hospitals in Wolverhampton, Cannock Chase Hospital in Cannock, other Trust Community sites and at our GP practices.

There can be more than 150 research projects happening at the Trust at any one time, involving the following clinical specialties:

  • Oncology
  • Rheumatology
  • Cardiovascular disease
  • Ophthalmology
  • Paediatrics
  • Renal
  • Dermatology
  • Respiratory
  • Gastroenterology
  • Obstetrics and Gynaecology
  • Haematology
  • Maternity
  • Infectious diseases
  • Stroke
  • Critical care
  • Surgery
  • Orthopaedics

Study set-up

83 new studies confirmed, including 31 commercial contract research studies.

397 study amendments were reviewed and confirmed

 

Study recruitment

1,596 participants recruited into 104 studies

 

Commercial/Non-commercial Study Participation

Non-commercial – 1394 (87 %)

Commercial – 202 (13%)

 

RWT was the 2nd highest recruiting organisation into NIHR adopted commercial studies in the West Midlands region in 2024/25.

 

 

Clinical Specialty Number of Participants Total
  Non-Commercial Studies Commercial Studies  
Cardiovascular 280 85 365
Dermatology 4 4
Gastroenterology 116 116
Haematology 49 19 68
Intensive Care 42 42
Neonatal 56 56
Neurology/Stroke 128 32 160
Obstetrics 135 135
Oncology 329 5  334
Ophthalmology 11 47 58
Orthopaedics 4 4
Paediatrics 22 22
Primary Care 8 8
Renal 49 3 52
Respiratory 2 2
Rheumatology 72 7 79
Surgery 34 34
Urology 44 44
Vascular 13 13
Total 1394 202 1596

 

 

Research governance describes a set of standards for the management of research that will:

  • Improve and maintain the scientific quality of research
  • Promote standards of good practice in the conduct of research
  • Ensure that all research undertaken in the Trust is ethical
  • Reduce adverse incidents during research projects
  • Prevent poor performance and misconduct during research

These principles are set out in the UK Policy Framework for Health and Social Care Research, 2023.

Research governance applies to all types of research undertaken at RWT by both Trust staff and external researchers working under honorary contracts for the organisation.

The standards are:

  • Trust management of research
  • Ethics
  • Quality of research
  • Conduct of research
  • Health and safety
  • Project and financial management
  • Management of intellectual property
  • Training in research skills
  • Consumer involvement in research design and planning
  • Information and dissemination of research results

The Trust aims to ensure ALL research is performed to the standards of the EU Directive for clinical trials and International Conference on Harmonisation Good Clinical Practice (ICH GCP) which constitute a standard set of principles to ensure data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are protected.

Research governance is implemented through the following mechanisms:

  • Trust Peer Review Committee approval
  • Research Ethics Committee approval
  • R&D/Trust approval
  • Quality Assurance training/assessments,
  • Auditing research

 

RWT recruitment by managing specialty:

  • Musculoskeletal disorders 337
  • Renal disorders 270
  • Cardiovascular disease 212
  • Reproductive health 209
  • Cancer 141
  • Children 123
  • Neurological disorders 63
  • Gastroenterology 55
  • Hepatology 55
  • Anaesthesia, perioperative 45
  • Surgery 44
  • Stroke 27
  • Respiratory disorders 11
  • Critical care 11
  • Ophthalmology 3
  • Trauma and emergency care 2
  • Diabetes 2
  • Mental health 1
  • Haematology 1

Commercial/non commercial:

  • Non-commercial – 63 (81.8 per cent)
  • Commercial – 14 (18.2 per cent)

Primary study design:

  • Interventional – 41 (52.3 per cent)
  • Observational – 26 (33.8 per cent)
  • Both – 10 (13.0 per cent)

The 2023-24 research participant survey, completed by 119 participants, showed the following:

  • 87 per cent felt fully informed about the study prior to taking part
  • 88 per cent felt valued for taking part in the research study
  • 92 felt they were always treated with courtesy and respect

NIHR West Midlands Regional Research Delivery NetworkHosted by RWT since 2014, the NIHR West Midlands Regional Research Delivery Network enables the health and care system to attract, optimise and deliver research across the region.

It is one of 12 Regional Research Delivery Networks in England, working together as one organisation – the NIHR Research Delivery Network (RDN) – with joint leadership.

Funded by the Department of Health and Social Care, the RDN’s vision is for the UK to be a global leader in the delivery of high-quality research that is inclusive, accessible, and improves health and care. Contact the Network at wm.rrdn@nihr.ac.uk.

The 2024-25 research participant survey, completed by 89 participants, showed the following:

· 84% felt fully informed about the study prior to taking part

· 82% felt valued for taking part in the research study

· 92% felt they were always treated with courtesy and respect

· 73% would consider taking part in research again

 

Patient 1

(We have protected the names of the patients involved as they wish to remain anonymous)

The following is feedback from a participant taking part in a multi-centre observation trial in psoriatic arthritis (a long-term condition that causes joint pain, swelling and stiffness), October 2024)

“I have pain in my feet, ankles, lower back, hands and wrists which has increased over the past 10 years or so, along with occasional psoriasis.

“I saw my Doctor just over a year ago at Cannock Chase Hospital when I was diagnosed with psoriatic arthritis.

“I was informed that I could take part in a clinical trial. It was only one morning every three months with blood tests in between.

“I signed up to the trial on my second visit to see the Doctor. I believe the results of tests and my overall experience of being on methotrexate for my arthritis may go towards furthering the research and treatment of the condition.

“My visits to clinical trials and the Doctor are four times a year.

“During my visit I complete a series of questions about how I have coped with my arthritis over the three months, how I have been feeling and the levels of pain I am experiencing.

“I have my blood pressure and weight taken and my Doctor will check me over to see what the levels of pain or discomfort are in my joints.

“I have only positive things to say about being a patient on a trial. The appointments only take a small amount of time and the experience is informative.

“The staff are extremely pleasant. I also find peace of mind that I am being well cared for.

“The only advice I would give someone considering taking part in a research study is DO IT. There’s nothing to it and it may well benefit you and possibly others too.”

The patient added: “I have had the best care at Cannock Chase Hospital on this trial.

“Everyone I have come into contact with – the Doctor, the trials team, even the Pharmacy and the staff who take the blood tests, are all so welcoming and friendly. Nothing is too much trouble.

“During the trial, my overall feeling was I was receiving excellent care and advice. If I ever needed to contact the team it was really straightforward and they always helped.

“As a lady of 59, I have an 86-year-old mother who has been in pain with arthritis for the past 40 years and is now bed-bound and crippled.

“I have a daughter of 28 who is starting to show early signs, of having joint pain – as I did – so I would urge anyone to give just a snippet of their time to take part in a trial to try to aid the advancement in treating conditions like arthritis.”

Patient 2

“’It’s Gleason scale 9 – so not ideal, and not operable’ was the blunt assessment of my prostate biopsy.

“’But don’t worry, it’s not the end of the world – there is much that can be done to improve things.’

“My wife and I sat quietly, trying to take in what we had just been told.

“Our introduction to cancer was brief and overwhelming. However, five minutes later, with a cup of tea in hand, a Nurse explained treatment would begin immediately and with every chance of a successful outcome. How true this turned out to be.

“We were given a large amount of written information showing where support could be found and that I would be referred to the Oncology clinic.

“I cannot emphasise how important this first step was. In 30 minutes I went from feeling very low to feeling that somehow it might turn out alright.

“Our first appointment with the trial team reinforced what I had experienced in Urology, that the future was not all gloomy.

“The meeting with Dr Sayers and his team was comprehensive and it ensured we both understood the situation and what could be done about it.

“I was offered a place on a trial, which I accepted. Again we left the appointment feeling good.

“At subsequent appointments we were kept fully up to date with treatment progress, had all our questions answered and became gradually drawn into the trial team ‘family’.

“The comprehensive care I have experienced took away all the negative feelings.

“Increasingly with each visit we became part of the team rather than an object of study.

“My wife was encouraged to play her part in assessing my wellbeing and at no time did we feel were not in good hands but confident of a successful outcome.

“The team was always available for any queries I might have had and we always experienced a friendly professionalism, which has been confidence building in itself.

“What would I say about embarking on a trial? Have it fully explained, ask every question you can think of, read the small print and don’t expect miracles.

“I am now in the seventh year of the trial having been see every 12 weeks, which in itself is a great comfort.

“During the trial and after I have never considered other than a successful outcome and supreme confidence in the team treating me. I have never felt alone.

“I feel privileged to be part of research and hoper my experience will be of help to future patients. The involvement of family is key. Thank you all.”